Biotech investors should keep a close eye on the progress in this huge potential market.
Third time should be the charm for AET as it nears a breakout.
Three small-cap biotechs with attractive risk/reward profiles.

Intermediate Trade: Celgene Real Money Pro($)

I prefer a very short-term, out-of-the-money vertical call spread expiring in May.
If you want to trade, you have to maintain short timeframes and be ready to flip.
Consider this BMY bullishly biased, near-the-money vertical call spread.
Apple's reported move into bio sensors could lead to even greater heights.

2 Biotech Pullback Targets Real Money Pro($)

Acadia and Neurocrine both have catalysts for growth; buy any weakness.
But it is not without some pain.
These stocks should be part of a strong first-quarter earnings season.

Columnist Conversations

View Chart »  View in New Window » XLY has met multiple upside targets, you may want to trail ...
WYN is ripping following this morning's earnings report. The lodging company is up over 8% and is in the numbe...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.